摘要
目的探讨喹硫平联合艾司西酞普兰治疗有精神病性症状抑郁症患者的疗效及安全性。方法对40例符合ICD-10诊断标准的有精神病性症状的抑郁症患者给予喹硫平[(303±118)mg/d]联合艾司西酞普兰[(10.8±1.8)mg/d]治疗,于治疗前及治疗后第2、4、6周应用Hamilton抑郁量表(HAMD-21)评定抑郁症状的变化,用简明精神病量表(BPRS)评定精神病性症状的变化,治疗中用不良反应量表(TESS)评定不良反应。结果与基线相比,HAMD和BPRS评分在治疗后2、4、6周均明显下降(P<0.01)。至治疗后6周,按疗效评定标准,抑郁症状的显效率(痊愈+显效)为75%,精神病性症状的显效率为70%。未发现严重不良反应。结论喹硫平联合艾司西酞普兰治疗有精神病性症状的单相抑郁有效,且安全性好。
Objective To study the efficacy and safety of quetiapine in combination with escitalopram in the treatment of psychotic depression. Methods Forty patients who met the criteria of unipolar psychotic depression in ICD -10 were treated with quetiapine [（303 ±118）mg/d ] combination with escitalopram [ （10.8 ± 1.8 ）mg/d ] tot 6 weeks. The efficacy was assessed with the 21 items Hamilton Depression Scale （ HAMD-21 ） and the Brief Psychiatric Rating Scale （ BPRS）, adverse reactions were assessed with the Treatment Emergent Symptom Scale （TESS）. Results Compared with those at the baseline, scores of HAMD-21 and BPRS decreased significantly at the 2nd,4th,6th weekend of the treatment （ P 〈 0.01 ）. At the end of the treatment, the improvement rate of depressive symptoms was 75 % and the improvement rate of psychotic symptoms was 70%. No serious side effects occurred. Conculsion Quetiapine combination with escitalopram is effective and safe in the treatment of unipolar psychotic depression.
出处
《精神医学杂志》
2011年第5期328-329,共2页
Journal of Psychiatry
基金
江苏省苏州市科技计划(社会发展)项目(编号:SZD0972)
江苏省太仓市科技计划项目(编号:TS0921)
